268 related articles for article (PubMed ID: 7461467)
21. Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Ahlberg J; Angelin B; Einarsson K
J Lipid Res; 1981 Mar; 22(3):410-22. PubMed ID: 7240966
[TBL] [Abstract][Full Text] [Related]
22. Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid.
Erlinger S; Le Go A; Husson JM; Fevery J
Hepatology; 1984; 4(2):308-14. PubMed ID: 6706305
[TBL] [Abstract][Full Text] [Related]
23. Biliary lipid metabolism in gallstone disease and during gallstone dissolution treatment.
Nilsell K
Acta Chir Scand Suppl; 1985; 528():1-38. PubMed ID: 3866449
[No Abstract] [Full Text] [Related]
24. Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid.
Stiehl A; Raedsch R; Czygan P; Götz R; Männer C; Walker S; Kommerell B
Gastroenterology; 1980 Dec; 79(6):1192-8. PubMed ID: 7439628
[TBL] [Abstract][Full Text] [Related]
25. Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid.
Key PH; Bonorris GG; Marks JW; Chung A; Schoenfield LJ
J Lab Clin Med; 1980 Jun; 95(6):816-26. PubMed ID: 7381293
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
[TBL] [Abstract][Full Text] [Related]
27. Cheno and urso compared and contrasted.
Dowling RH
Acta Med Port; 1983 Jan; 4(1):51-62. PubMed ID: 6337454
[No Abstract] [Full Text] [Related]
28. Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. Effects on biliary lipid metabolism during weight maintenance and weight reduction.
Mazzella G; Bazzoli F; Festi D; Ronchi M; Aldini R; Roda A; Grigolo B; Simoni P; Villanova N; Roda E
Gastroenterology; 1991 Aug; 101(2):490-6. PubMed ID: 2065925
[TBL] [Abstract][Full Text] [Related]
29. Total protein content of human gallbladder bile: relation to cholesterol gallstone disease and effects of treatment with bile acids and aspirin.
Sahlin S
Eur J Surg; 1996 Jun; 162(6):463-9. PubMed ID: 8817223
[TBL] [Abstract][Full Text] [Related]
30. Treatment of radiolucent gallstones with CDCA or UDCA. A multicenter trial.
Polli EE; Bianchi PA; Conte D; Sironi L
Digestion; 1981; 22(4):185-91. PubMed ID: 7030835
[TBL] [Abstract][Full Text] [Related]
31. Gallstone dissolution treatment with a combination of chenodeoxycholic and ursodeoxycholic acids. Studies of safety, efficacy and effects on bile lithogenicity, bile acid pool, and serum lipids.
Roehrkasse R; Fromm H; Malavolti M; Tunuguntla AK; Ceryak S
Dig Dis Sci; 1986 Oct; 31(10):1032-40. PubMed ID: 3757719
[TBL] [Abstract][Full Text] [Related]
32. Clinical studies on cheno- and ursodeoxycholic acid treatment for gallstone dissolution.
Iwamura K
Hepatogastroenterology; 1980 Feb; 27(1):26-34. PubMed ID: 7203354
[TBL] [Abstract][Full Text] [Related]
33. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile.
Igimi H; Asakawa S; Watanabe D; Shimura H
Gastroenterol Jpn; 1983 Apr; 18(2):93-7. PubMed ID: 6852442
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of the effects of an equal dose of 15 mg/kg/day of chenodeoxycholic and ursodeoxycholic acid on the composition of biliary lipids and acids in the bile in radiotransparent biliary lithiasis].
Garrido G; Breto M; Alegre B; Pérez Aguilar F; Berenguer J
Rev Esp Enferm Apar Dig; 1983 Oct; 64(4):261-9. PubMed ID: 6658120
[No Abstract] [Full Text] [Related]
35. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action.
Maton PN; Murphy GM; Dowling RH
Lancet; 1977 Dec 24-31; 2(8052-8053):1297-301. PubMed ID: 74722
[TBL] [Abstract][Full Text] [Related]
36. [Gallstone solubilizers].
Ighimi H
Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1170-3. PubMed ID: 6503981
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cholesterol gallstones with litholytic bile acids.
Salen G; Tint GS; Shefer S
Gastroenterol Clin North Am; 1991 Mar; 20(1):171-82. PubMed ID: 2022420
[TBL] [Abstract][Full Text] [Related]
38. Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Coyne MJ; Bonorris GG; Goldstein LI; Schoenfield LJ
J Lab Clin Med; 1976 Feb; 87(2):281-91. PubMed ID: 1245792
[TBL] [Abstract][Full Text] [Related]
39. Value of serum determinations for prediction of increased ursodeoxycholic and chenodeoxycholic levels in bile.
Bazzoli F; Fromm H; Roda A; Tunuguntla AK; Roda E; Barbara L; Amin P
Dig Dis Sci; 1985 Jul; 30(7):650-4. PubMed ID: 4006647
[TBL] [Abstract][Full Text] [Related]
40. Early morphologic and enzymatic changes in livers of rats treated with chenodeoxycholic and ursodeoxycholic acids.
Shefer S; Zaki FG; Salen G
Hepatology; 1983; 3(2):201-8. PubMed ID: 6832710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
